Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.

Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.
复制标题

DOI:
10.1002/cncr.25259
复制
发表时间:
2010-10-15
期刊:
影响因子:
6.2
通讯作者:
Wadehra, Madhuri
Wadehra, Madhuri
中科院分区:
医学1区
文献类型:
--
作者:
Habeeb, Omar;Goodglick, Lee;Soslow, Robert A.;Rao, Rajiv G.;Gordon, Lynn K.;Schirripa, Osvaldo;Horvath, Steve;Braun, Jonathan;Seligson, David B.;Wadehra, Madhuri

文献摘要

参考文献

被引文献

相似文献

子宫内膜癌是一种常见的恶性肿瘤。它通常发生在子宫内膜增生之前,其治疗和肿瘤进展的风险各不相同。以前,我们已经表明,tetraspan蛋白上皮膜蛋白-2(EMP 2)是EC侵袭性和生存的预后指标。在这里,我们验证了EMP 2在EC中的表达,并进一步研究EMP 2在癌前病变中的表达是否是EC发展的早期预后生物标志物。组织芯片(TMA)的良性和恶性子宫内膜样本的广泛代表性。TMA包含一个异时队列的病例,这些病例来自发生或未发生EC的个体。使用免疫组织化学评估EMP 2表达的强度和频率。从良性到增生,再到子宫内膜癌,EMP 2的平均表达呈阶梯式显著增加。此外,在潜在的癌前病变病例中EMP 2表达的详细分析表明,EMP 2阳性是EC发展的强有力预测因子。EMP 2是癌前病变中EC发展的早期预测因子。此外,结合我们以前的研究结果,这些结果验证了EMP 2作为EC发展的新生物标志物。
Endometrial cancer (EC) is a common malignancy worldwide. It is often preceded by endometrial hyperplasia, whose management and risk of neoplastic progression vary. Previously, we have shown that the tetraspan protein Epithelial Membrane Protein-2 (EMP2) is a prognostic indicator for EC aggressiveness and survival. Here we validate the expression of EMP2 in EC, and further examine whether EMP2 expression within preneoplastic lesions is an early prognostic biomarker for EC development. A tissue microarray (TMA) was constructed with a wide representation of benign and malignant endometrial samples. The TMA contains a metachronous cohort of cases from individuals who either developed or did not develop EC. Intensity and frequency of EMP2 expression were assessed using immunohistochemistry. There was a stepwise, statistically-significant increase in the average EMP2 expression from benign to hyperplasia to atypia to EC. Furthermore, detailed analysis of EMP2 expression in potentially premalignant cases demonstrated that EMP2 positivity was a strong predictor for EC development. EMP2 is an early predictor of EC development in preneoplastic lesions. In addition, combined with our previous findings, these results validate that EMP2 as a novel biomarker for EC development.
DOI: 10.1158/0008-5472.can-08-1154
发表时间: 2008-07-15
期刊: Cancer research
影响因子: 11.2
作者:
Lacey JV Jr;Mutter GL;Ronnett BM;Ioffe OB;Duggan MA;Rush BB;Glass AG;Richesson DA;Chatterjee N;Langholz B;Sherman ME
通讯作者: Sherman ME
DOI: 10.1158/0008-5472.can-07-2607
发表时间: 2007-11-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Mah, Vei;Seligson, David B.;Goodglick, Lee
通讯作者: Goodglick, Lee
DOI: 10.1097/pas.0b013e318159a2a0
发表时间: 2008-05-01
影响因子: 5.6
作者:
Allison, Kimberly H.;Reed, Susan D.;Garcia, Rochelle L.
通讯作者: Garcia, Rochelle L.
DOI: 10.1177/107327480901600102
发表时间: 2009-01-01
期刊: CANCER CONTROL
影响因子: 2.6
作者:
Bansal, Nisha;Yendluri, Vimala;Wenham, Robert M.
通讯作者: Wenham, Robert M.
DOI: 10.1038/nature03672
发表时间: 2005-06-30
期刊: NATURE
影响因子: 64.8
作者:
Seligson, DB;Horvath, S;Kurdistani, SK
通讯作者: Kurdistani, SK